Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
25 March 2026
Read original ↗
🅇 This trial is currently recruiting participants in the UK
Speak to your GP or specialist first. They can help you understand if you might be eligible and what taking part would involve.
🔬 This trial is currently recruiting participants
If you match the criteria below, you may be able to take part. Ask your doctor about this trial or contact the trial team directly.
Status
Recruiting
Trial Phase
PHASE4
Who Can Join
ALL
Age Range
18 Years – Any
About This Trial
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma.
The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.
Run by
Sanofi
⚕️ Before you apply: Talk to your GP or specialist about whether this trial might be right for you. Never stop existing treatment without medical advice. Trial ID: NCT05097287